• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    6/22/22 1:43:41 PM ET
    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTTX alert in real time by email

     

    Gainers

    • Omeros (NASDAQ:OMER) shares increased by 23.7% to $2.71 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 1.3 million shares, making up 150.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $169.9 million.
    • Vor Biopharma (NASDAQ:VOR) stock moved upwards by 23.62% to $5.6. The current volume of 96.9K shares is 93.3% of Vor Biopharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $210.5 million.
    • Better Therapeutics (NASDAQ:BTTX) shares increased by 22.75% to $1.83. As of 13:30 EST, this security is trading at a volume of 297.7K shares, making up 4.5% of its average full-day volume over the last 100 days. The company's market cap stands at $43.1 million.
    • Mustang Bio (NASDAQ:MBIO) shares moved upwards by 22.62% to $0.76. As of 13:30 EST, Mustang Bio's stock is trading at a volume of 2.5 million, which is 262.7% of its average full-day volume over the last 100 days. The company's market cap stands at $78.3 million.
    • Vaccitech (NASDAQ:VACC) stock increased by 20.61% to $5.5. The market value of their outstanding shares is at $204.6 million.
    • Durect (NASDAQ:DRRX) shares increased by 20.58% to $0.55. Trading volume for this security as of 13:30 EST is 1.0 million, which is 113.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $124.1 million.

    Losers

    • Zynex (NASDAQ:ZYXI) shares declined by 22.2% to $6.9 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 1.1 million, which is 251.8% of its average full-day volume over the last 100 days. The company's market cap stands at $265.6 million.
    • 4d pharma (NASDAQ:LBPS) stock decreased by 13.64% to $1.52. The company's market cap stands at $34.2 million.
    • Mereo BioPharma Group (NASDAQ:MREO) shares declined by 13.03% to $1.47. Trading volume for Mereo BioPharma Group's stock is 15.4 million as of 13:30 EST. This is 378.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $171.9 million.
    • Viracta Therapeutics (NASDAQ:VIRX) shares decreased by 11.5% to $2.36. As of 13:30 EST, this security is trading at a volume of 795.5K shares, making up 326.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $88.5 million.
    • GreenLight Biosciences (NASDAQ:GRNA) stock declined by 10.72% to $3.38. As of 13:30 EST, GreenLight Biosciences's stock is trading at a volume of 70.3K, which is 30.3% of its average full-day volume over the last 100 days. The company's market cap stands at $415.7 million.
    • NantHealth (NASDAQ:NH) shares declined by 10.02% to $0.47. The current volume of 87.1K shares is 92.7% of NantHealth's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $54.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BTTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTX
    $DRRX
    $GRNA
    $LBPS

    CompanyDatePrice TargetRatingAnalyst
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    Vor Biopharma Inc.
    $VOR
    3/19/2026$30.00Overweight
    Wells Fargo
    Vor Biopharma Inc.
    $VOR
    1/9/2026$50.00Buy
    Citigroup
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Vor Biopharma Inc.
    $VOR
    12/17/2025Buy
    TD Cowen
    Vor Biopharma Inc.
    $VOR
    12/9/2025$43.00Overweight
    Analyst
    Vor Biopharma Inc.
    $VOR
    11/25/2025$9.00Neutral
    Wedbush
    Vor Biopharma Inc.
    $VOR
    10/15/2025$64.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Announces $75 Million Private Placement with TCGX

    BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. The fin

    3/27/26 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves

    3/26/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 215,700 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 46,235 shares of Vor Bio's common stock to 8 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor B

    3/23/26 4:30:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Vor Biopharma with a new price target

    Wells Fargo initiated coverage of Vor Biopharma with a rating of Overweight and set a new price target of $30.00

    3/19/26 8:27:43 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup initiated coverage on Vor Biopharma with a new price target

    Citigroup initiated coverage of Vor Biopharma with a rating of Buy and set a new price target of $50.00

    1/9/26 9:08:27 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $11,357 worth of shares (5,917 units at $1.92), increasing direct ownership by 0.22% to 2,672,529 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/26/25 3:41:18 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asen R Scott bought $386,666 worth of shares (204,220 units at $1.89), increasing direct ownership by 5% to 2,666,612 units (SEC Form 4)

    4 - DURECT CORP (0001082038) (Issuer)

    8/22/25 6:10:18 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for POSIMIR

    Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

    2/2/21 7:24:30 AM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Omeros Corporation

    SCHEDULE 13G/A - OMEROS CORP (0001285819) (Subject)

    3/27/26 11:04:36 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vor Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vor Biopharma Inc. (0001817229) (Filer)

    3/27/26 8:03:02 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by Mereo BioPharma Group plc

    PRE 14A - Mereo BioPharma Group plc (0001719714) (Filer)

    3/27/26 6:24:11 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ekblom Anders

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:16 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bender Jeremy

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:15 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Pakianathan Deepika

    4 - Mereo BioPharma Group plc (0001719714) (Issuer)

    2/27/26 4:30:13 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by DURECT Corporation

    SC 13G/A - DURECT CORP (0001082038) (Subject)

    11/19/24 5:10:25 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viracta Therapeutics Inc.

    SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

    11/14/24 4:33:15 PM ET
    $VIRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Leadership Updates

    Live Leadership Updates

    View All

    Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

    BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors. "Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the

    12/23/25 4:01:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer

    BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Dr. Sokolove brings more than two decades of clinical and translational experience in rheumatology and autoimmune disease research and development to the company's leadership team. "We are thrilled to welcome Jeremy to Vor Bio," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His deep clinical expertise as a rheumatologist, coupled with his strong track record in industry and as a thought leader in autoimmune and inflammato

    11/3/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTX
    $DRRX
    $GRNA
    $LBPS
    Financials

    Live finance-specific insights

    View All

    Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

    Omeros Corporation (NASDAQ:OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click here or visit the "Upcoming Events" section of the Investor Relations page of Omeros' website. A replay of the call will be available for 90 days in the "Archived Events" section of the Inves

    3/26/26 8:45:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

    – Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno

    12/24/25 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care